An NIH-funded study from the Cleveland Clinic suggests that testosterone may help suppress glioblastoma growth in men, potentially paving the way for new brain cancer treatments.
A recent study funded by the National Institutes of Health (NIH) and conducted at the Cleveland Clinic has revealed that testosterone may play a role in suppressing the growth of glioblastoma, one of the most aggressive forms of brain cancer. This groundbreaking research could open new avenues for treatment and clinical trials aimed at combating this deadly disease.
Published in the journal *Nature*, the study challenges long-standing beliefs regarding male hormones and their relationship with brain cancer. Researchers found compelling evidence indicating that testosterone may actually inhibit the growth of glioblastoma tumors in men, a finding that could significantly alter treatment strategies for this condition.
In their investigation, scientists explored the interactions between androgen hormones, including testosterone, and glioblastoma. The research team discovered that reducing testosterone levels in male mice led to accelerated tumor growth and diminished immune responses within the brain. Notably, glioblastoma is diagnosed more frequently in men than in women, prompting researchers to suspect that male hormones might contribute to the disease’s prevalence. However, these new findings suggest a contrary effect.
“This outcome is a welcome surprise and may potentially offer a lead for new treatments for a kind of cancer that is deadlier in men,” said Anthony Letai, a researcher involved in the study, in a statement released by the NIH.
The study indicated that testosterone may help regulate immune activity in the brain. When androgen levels decreased in laboratory models, the hypothalamus-pituitary-adrenal axis—a stress-response system—became overactive. This overactivity triggered inflammation and created an environment that suppressed the immune system, allowing tumors to grow more aggressively.
Additionally, the research team analyzed medical data from over 1,300 men diagnosed with glioblastoma using the NIH’s SEER cancer database. The findings revealed that men receiving testosterone supplementation for unrelated medical conditions had a 38% lower risk of death compared to those not on testosterone therapy. However, researchers cautioned that these results do not definitively prove that testosterone directly enhances survival rates in humans.
Justin Lathia, the senior author of the study, noted that the immune environment of the brain is markedly different from that of other body parts, making the effects of hormones more complex to predict. These findings arrive at a time when researchers are increasingly investigating why certain cancers exhibit different behaviors in men and women. NIH-funded studies have also been examining the influence of sex chromosomes and hormones on tumor biology and immune responses.
The next phase of research will involve clinical trials aimed at determining whether testosterone-based therapies could be safely administered to specific glioblastoma patients.
Industry experts have welcomed the study’s findings. Himanshu Shah, Executive Chairman of Marius Pharmaceuticals, which produces the testosterone therapy Kyzatrex, described the research as “momentous.”
“Though testosterone supplementation is not yet a standard of care, it should be considered based on the influential results of such a large study. Patients will benefit from this,” Shah stated.
Kyzatrex, which has received approval from the U.S. Food and Drug Administration (FDA), is indicated for adult men with low or deficient testosterone levels. Earlier this year, Marius Pharmaceuticals announced plans for a new post-marketing clinical study to evaluate a potential label expansion for Kyzatrex CIII capsules in men aged 65 to 80 suffering from hypogonadism. As men age, declining testosterone levels can exacerbate various health issues, impacting energy, muscle strength, mobility, metabolism, and overall quality of life. Through this study, researchers aim to gain a deeper understanding of how Kyzatrex may enhance health outcomes and daily functioning in older patients.
Testosterone therapy has been successfully utilized for nearly a century, including for women undergoing menopause treatment. However, its progress faced significant hurdles after testosterone was classified as a Schedule III controlled substance in the United States during the 1980s. Critics of this classification argue that it was influenced more by political pressures than by scientific evidence, despite opposition from the FDA and the American Medical Association at the time.
The implications of this NIH-funded study are profound, as they not only challenge existing perceptions of testosterone’s role in brain cancer but also highlight the potential for new therapeutic strategies to combat glioblastoma in men.
According to The American Bazaar, the findings could reshape treatment approaches and encourage further research into the relationship between male hormones and cancer.